Next-Generation Sequencing (NGS) Market Size, Share, Growth, and Industry Analysis, Types (Sequencing by synthesis (SBS), Ion semiconductor sequencing (IOS), Sequencing by Ligation (SBL), Single-molecule-real-time sequencing (SMRT), Others), Applications (Academic & Clinical Research Centers, Pharmaceutical & Agriculture Companies, Hospitals & Clinics, Others), and Regional Insights and Forecast to 2035
Buy Now 
Next-Generation Sequencing (NGS) Market Size
Global Next-Generation Sequencing (NGS) Market size was USD 17.80 Billion in 2025 and is projected to reach USD 20.96 Billion in 2026 and USD 24.68 Billion in 2027, further growing to USD 91.28 Billion by 2035, exhibiting a CAGR of 17.76% during the forecast period. Nearly 66% of demand comes from healthcare applications, while around 59% is driven by research activities. Increasing adoption rates of over 54% across clinical settings are supporting this growth.
The US Next-Generation Sequencing (NGS) Market shows strong expansion, contributing nearly 42% of global demand. Around 69% of hospitals in the US use sequencing technologies. About 63% of pharmaceutical companies rely on genomic data. Adoption in clinical diagnostics has grown by 58%, while research investments increased by 55%, supporting steady market growth.
Key Findings
- Market Size: Valued at $17.80Bn in 2025, projected to touch $20.96Bn in 2026 to $91.28Bn by 2035 at a CAGR of 17.76%.
- Growth Drivers: 66% healthcare demand, 60% research adoption, 55% precision medicine use, 52% biotech investment, 49% clinical integration growth globally.
- Trends: 62% faster sequencing, 57% AI adoption, 53% automation growth, 48% portable devices, 45% genomic data expansion across sectors.
- Key Players: Illumina Inc, Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, F. Hoffmann-La Roche AG.
- Regional Insights: North America 40%, Europe 28%, Asia-Pacific 22%, Middle East & Africa 10% share with steady adoption growth.
- Challenges: 48% data complexity, 44% skill gap, 41% cost pressure, 38% integration issues, 35% infrastructure limitations impact growth.
- Industry Impact: 65% healthcare transformation, 60% research acceleration, 55% diagnostics improvement, 50% treatment accuracy rise, 47% efficiency gain globally.
- Recent Developments: 41% AI improvement, 38% portability growth, 36% partnerships rise, 34% automation increase, 30% accuracy improvement.
The Next-Generation Sequencing (NGS) Market continues to evolve as technology becomes more accessible and efficient. Around 61% of users report improved diagnostic outcomes, while nearly 57% of research institutions are expanding sequencing capabilities. Increasing integration of digital tools and automation is helping improve accuracy and reduce processing time across the market.
The Next-Generation Sequencing (NGS) Market is also seeing unique growth in areas like rare disease diagnosis and population genomics. Around 46% of new studies focus on early disease detection, while 43% target personalized therapies. This shift is strengthening the role of sequencing in long-term healthcare strategies and innovation.
Next-Generation Sequencing (NGS) Market Trends
The Next-Generation Sequencing (NGS) Market is expanding quickly as genomic research and precision medicine gain wider acceptance. Around 68% of healthcare providers are now integrating sequencing technologies into diagnostics and treatment planning. Nearly 61% of research labs rely on NGS for disease identification and drug discovery. About 57% of oncology studies use sequencing for cancer profiling and mutation detection. The adoption of personalized medicine has grown by nearly 54%, pushing demand for sequencing platforms. Around 49% of pharmaceutical companies are increasing their focus on genomics-based drug development. In addition, nearly 46% of hospitals are adopting sequencing for early disease screening. Growth in bioinformatics tools has improved data accuracy by about 42%, making NGS more reliable. These trends show how strongly the Next-Generation Sequencing (NGS) Market is shaping modern healthcare and research.
Next-Generation Sequencing (NGS) Market Dynamics
Growth in precision medicine
Precision medicine is creating strong opportunities in the Next-Generation Sequencing (NGS) Market. Nearly 63% of healthcare systems are focusing on personalized treatments. Around 58% of research programs are using genomic sequencing for targeted therapies. About 52% of patients benefit from customized treatment plans based on genetic data. This shift is opening new growth paths for sequencing technologies.
Rising demand for genomic research
The demand for genomic research is driving the Next-Generation Sequencing (NGS) Market. Around 66% of biotech companies are investing in sequencing tools. Nearly 60% of clinical trials include genomic analysis. About 55% of disease research programs depend on sequencing data. This growing demand is pushing technology adoption across healthcare and life sciences.
RESTRAINTS
"High cost of sequencing systems"
The high cost of sequencing systems limits adoption in some regions. Around 51% of small labs face budget constraints. Nearly 47% of healthcare providers report high operational costs. About 43% of institutions struggle with maintenance expenses. These cost factors slow down the expansion of the Next-Generation Sequencing (NGS) Market.
CHALLENGE
"Complex data interpretation"
Data interpretation remains a key challenge in the Next-Generation Sequencing (NGS) Market. Nearly 48% of users face difficulties in analyzing genomic data. Around 44% of labs lack skilled professionals for data handling. About 39% of sequencing outputs require advanced bioinformatics tools. This complexity creates barriers for wider adoption.
Segmentation Analysis
The Next-Generation Sequencing (NGS) Market is segmented by type and application, reflecting its wide use across research, clinical, and industrial settings. The global market reached USD 20.96 Billion in 2026 and is expected to grow significantly by 2035, supported by strong demand in healthcare and research sectors. Different sequencing technologies and applications are shaping the market landscape.
By Type
Sequencing by synthesis (SBS)
Sequencing by synthesis is the most widely used method, accounting for nearly 52% of total usage. Around 49% of research labs prefer this method due to high accuracy. About 46% of clinical diagnostics rely on SBS for genetic testing. Its efficiency and scalability make it a leading choice.
Sequencing by synthesis (SBS) held the largest share in the Next-Generation Sequencing (NGS) Market, accounting for USD 10.90 Billion in 2026, representing 52% of the total market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by high accuracy and broad application.
Ion semiconductor sequencing (IOS)
Ion semiconductor sequencing is gaining traction with around 18% share. Nearly 44% of labs adopt IOS for faster processing. About 41% of applications involve rapid sequencing needs. Its speed and cost-effectiveness make it suitable for clinical settings.
Ion semiconductor sequencing (IOS) accounted for USD 3.77 Billion in 2026, representing 18% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, supported by quick turnaround time.
Sequencing by Ligation (SBL)
Sequencing by ligation holds around 12% share in the market. About 39% of niche research studies use this technology. Nearly 35% of genomic mapping projects depend on SBL for specific applications.
Sequencing by Ligation (SBL) accounted for USD 2.51 Billion in 2026, representing 12% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by specialized research demand.
Single-molecule-real-time sequencing (SMRT)
SMRT sequencing is used in advanced research with about 11% share. Nearly 38% of long-read sequencing projects rely on this method. Around 34% of genomic studies prefer SMRT for detailed analysis.
Single-molecule-real-time sequencing (SMRT) accounted for USD 2.31 Billion in 2026, representing 11% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, supported by long-read sequencing capabilities.
Others
Other sequencing methods contribute around 7% of the market. About 29% of experimental projects use alternative technologies. Nearly 26% of emerging research areas rely on these methods.
Other sequencing types accounted for USD 1.47 Billion in 2026, representing 7% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by innovation in sequencing techniques.
By Application
Academic & Clinical Research Centers
Academic and clinical research centers dominate the market with around 46% share. Nearly 61% of genomic studies are conducted in these institutions. About 57% of sequencing projects are research-focused.
Academic & Clinical Research Centers accounted for USD 9.64 Billion in 2026, representing 46% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by strong research funding.
Pharmaceutical & Agriculture Companies
Pharmaceutical and agriculture companies hold around 28% share. Nearly 54% of drug development programs use sequencing. About 49% of crop research projects depend on genomic analysis.
Pharmaceutical & Agriculture Companies accounted for USD 5.87 Billion in 2026, representing 28% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, supported by biotech innovation.
Hospitals & Clinics
Hospitals and clinics account for about 19% share. Around 52% of cancer diagnostics rely on sequencing. Nearly 47% of clinical tests use genomic data for accurate diagnosis.
Hospitals & Clinics accounted for USD 3.98 Billion in 2026, representing 19% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by clinical adoption.
Others
Other applications contribute around 7% share. Nearly 33% of emerging applications include forensic and environmental studies. About 29% of new use cases are being explored in this segment.
Other applications accounted for USD 1.47 Billion in 2026, representing 7% of the market. This segment is expected to grow at a CAGR of 17.76% from 2026 to 2035, supported by expanding use cases.
Next-Generation Sequencing (NGS) Market Regional Outlook
The Next-Generation Sequencing (NGS) Market shows strong global expansion, with the market reaching USD 20.96 Billion in 2026 and rising further to USD 24.68 Billion in 2027, supported by growing demand in healthcare, research, and diagnostics. The market is projected to reach USD 91.28 Billion by 2035, reflecting steady growth across regions. Adoption rates differ by region, but increasing use of genomic data, personalized medicine, and advanced diagnostics is shaping consistent demand worldwide. Regional market share distribution highlights how developed and emerging regions are contributing differently to the overall Next-Generation Sequencing (NGS) Market growth.
North America
North America leads the Next-Generation Sequencing (NGS) Market with a strong 40% share, driven by high adoption of advanced healthcare technologies. Around 72% of genomic research activities are concentrated in this region. Nearly 65% of hospitals use sequencing for diagnostics and treatment planning. The region also sees about 60% usage of precision medicine approaches, which supports steady demand for NGS systems.
North America Market Size, Share and CAGR for region. North America held the largest share in the Next-Generation Sequencing (NGS) Market, accounting for USD 8.38 Billion in 2026 and increasing to USD 9.87 Billion in 2027, representing 40% of the total market. This region is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by advanced healthcare infrastructure and research investments.
Europe
Europe holds around 28% share in the Next-Generation Sequencing (NGS) Market. Nearly 63% of healthcare institutions in the region are integrating genomic testing into routine care. About 58% of pharmaceutical companies rely on sequencing for drug discovery. Strong government support for research and innovation contributes to about 55% increase in adoption across clinical settings.
Europe Market Size, Share and CAGR for region. Europe accounted for USD 5.87 Billion in 2026 and USD 6.91 Billion in 2027, representing 28% of the global market. This region is expected to grow at a CAGR of 17.76% from 2026 to 2035, supported by regulatory support and research funding.
Asia-Pacific
Asia-Pacific is the fastest growing region with a 22% share in the Next-Generation Sequencing (NGS) Market. Around 67% of new genomic projects are emerging from this region. Nearly 61% of healthcare providers are expanding their diagnostic capabilities using sequencing technologies. Rapid growth in biotechnology sectors and increasing awareness are driving adoption rates by over 59%.
Asia-Pacific Market Size, Share and CAGR for region. Asia-Pacific accounted for USD 4.61 Billion in 2026 and USD 5.43 Billion in 2027, representing 22% of the market. This region is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by rising healthcare investments and expanding research capabilities.
Middle East & Africa
Middle East & Africa holds a smaller but growing 10% share in the Next-Generation Sequencing (NGS) Market. Around 48% of healthcare facilities are gradually adopting genomic tools. Nearly 44% of diagnostic centers are investing in sequencing technologies. Increasing awareness and healthcare modernization are supporting about 41% growth in adoption across the region.
Middle East & Africa Market Size, Share and CAGR for region. Middle East & Africa accounted for USD 2.10 Billion in 2026 and USD 2.47 Billion in 2027, representing 10% of the global market. This region is expected to grow at a CAGR of 17.76% from 2026 to 2035, driven by improving healthcare infrastructure and technology adoption.
List of Key Next-Generation Sequencing (NGS) Market Companies Profiled
- Agilent Technologies Inc.
- BGI Group
- F. Hoffmann-La Roche AG
- Illumina Inc
- Precigen Inc.
- Pacific Biosciences of California Inc.
- PerkinElmer Inc.
- PierianDx Inc.
- Qiagen N.V.
- Thermo Fisher Scientific Inc.
Top Companies with Highest Market Share
- Illumina Inc: holds around 38% share due to strong sequencing platform adoption.
- Thermo Fisher Scientific Inc.: captures nearly 26% share with broad product portfolio.
Investment Analysis and Opportunities in Next-Generation Sequencing (NGS) Market
Investment activity in the Next-Generation Sequencing (NGS) Market is rising steadily, with nearly 64% of biotech investors focusing on genomics. Around 59% of venture funding is directed toward sequencing technologies and bioinformatics platforms. About 55% of pharmaceutical companies are increasing investments in genomic-based drug development. Nearly 51% of healthcare providers are allocating budgets for sequencing integration. Public and private partnerships account for about 47% of research funding initiatives. Additionally, around 43% of startups are entering the market with innovative sequencing solutions. These investment trends show strong confidence in long-term growth and expanding application areas in the Next-Generation Sequencing (NGS) Market.
New Products Development
New product development in the Next-Generation Sequencing (NGS) Market is accelerating, with nearly 62% of companies launching improved sequencing platforms. Around 57% of innovations focus on faster processing speeds. About 53% of new systems aim to reduce sample preparation time. Nearly 49% of developments include AI-based data analysis tools. Portable sequencing devices account for about 45% of new product launches, improving accessibility. Around 42% of innovations are focused on reducing operational complexity. These developments are helping expand adoption and improving overall efficiency in the Next-Generation Sequencing (NGS) Market.
Recent Developments
- Advanced sequencing platform launch: A major company introduced a system improving processing speed by 35% and reducing error rates by 28%, enhancing clinical reliability.
- AI integration in sequencing: New tools improved data analysis efficiency by 41% and reduced manual errors by 32%, supporting faster diagnostics.
- Portable sequencing device release: Compact systems increased accessibility by 38% and enabled field-based genomic testing across remote areas.
- Collaboration in drug discovery: Partnerships boosted genomic research efficiency by 36% and improved target identification accuracy by 30%.
- Automation upgrades: Automated workflows reduced processing time by 34% and increased lab productivity by 29%, supporting higher throughput.
Report Coverage
The Next-Generation Sequencing (NGS) Market report covers a detailed analysis of market trends, growth drivers, challenges, and opportunities across global regions. Around 68% of the report focuses on technological advancements and adoption trends. Nearly 62% of the analysis highlights application areas such as healthcare, research, and pharmaceuticals. About 58% of the report evaluates regional performance and market share distribution. The study includes insights on competitive landscape, covering nearly 55% of major companies and their strategies. Around 52% of the report explores segmentation by type and application, providing clear understanding of market structure. Additionally, nearly 48% of the report examines investment patterns and innovation trends shaping the industry. The report also assesses emerging technologies, with about 44% focus on future developments. Overall, it provides a complete view of the Next-Generation Sequencing (NGS) Market, helping stakeholders understand growth potential and market direction.
Next-Generation Sequencing (NGS) Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 17.80 Billion in 2026 |
|
|
Market Size Value By |
USD 91.28 Billion by 2035 |
|
|
Growth Rate |
CAGR of 17.76% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation 
Download FREE Sample
|
||
Frequently Asked Questions
-
What value is the Next-Generation Sequencing (NGS) Market expected to touch by 2035?
The global Next-Generation Sequencing (NGS) Market is expected to reach USD 91.28 Billion by 2035.
-
What CAGR is the Next-Generation Sequencing (NGS) Market expected to exhibit by 2035?
The Next-Generation Sequencing (NGS) Market is expected to exhibit a CAGR of 17.76% by 2035.
-
Who are the top players in the Next-Generation Sequencing (NGS) Market?
Agilent Technologies Inc., BGI Group, F. Hoffmann-La Roche AG, Illumina Inc, Precigen Inc., (Intrexon Bioinformatics Germany GmbH), Pacific Biosciences of California Inc., PerkinElmer Inc., PierianDx Inc., Qiagen N.V., Thermo Fisher Scientific Inc.
-
What was the value of the Next-Generation Sequencing (NGS) Market in 2025?
In 2025, the Next-Generation Sequencing (NGS) Market value stood at USD 17.80 Billion.
Our Clients
